文献速递肝病

不同治疗线数下原发性胆汁性胆管炎合并肝硬化患者失代偿事件的预测因素

Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy.
PubMed 文献 · Hepatology · 2024-03-06

多中心研究纳入388例原发性胆汁性胆管炎合并肝硬化患者,比较二线治疗与熊去氧胆酸对失代偿事件的影响。真实世界中熊去氧胆酸组失代偿发生率较低,但倾向性评分匹配后两组相似(熊去氧胆酸3.77 vs 二线治疗4.5/100人年)。晚期肝病而非二线治疗与失代偿事件相关,奥贝胆酸和贝特类药物的生化应答可降低失代偿风险。

要点

  • 晚期原发性胆汁性胆管炎而非奥贝胆酸或贝特类药物与失代偿事件相关
  • 奥贝胆酸应答(52%患者达到)与胆红素和AST相关,应答者失代偿风险降低(sHR 0.23)
  • 贝特类应答(55%患者达到)与AST相关,应答者失代偿风险降低(sHR 0.36)

核心结论

  • 晚期原发性胆汁性胆管炎而非奥贝胆酸和贝特类药物与失代偿事件相关,因此决定这些药物管理时应考虑生化和临床变量。
  • 对奥贝胆酸和贝特类药物的阳性应答可降低失代偿风险。

研究设计与样本

  • 多中心研究,纳入西班牙ColHai注册库中388例原发性胆汁性胆管炎合并肝硬化患者。
  • 肝硬化由活检(20%)、超声(59%)或瞬时弹性成像(21%)定义,临床显著门脉高压由静脉曲张和脾肿大定义。
  • 熊去氧胆酸、贝特类(n=93)和奥贝胆酸(n=104)的应答分别由Paris-II和PBC OCA国际疗效研究标准确定。

主要发现

  • 真实世界人群中熊去氧胆酸组失代偿发生率低于奥贝胆酸或贝特类组,但倾向性评分匹配后两组相似(熊去氧胆酸3.77 vs 二线治疗4.5/100人年)。
  • GGT、白蛋白、血小板、临床显著门脉高压和熊去氧胆酸应答与失代偿事件相关。
  • 奥贝胆酸应答(52%患者达到)与胆红素(OR 0.21 [95%CI: 0.06-0.73])和AST(OR 0.97 [95%CI: 0.95-0.99])相关;贝特类应答(55%患者达到)与AST(OR 0.96 [95%CI: 0.95-0.98])相关。
  • 奥贝胆酸治疗患者中,药物应答(sHR 0.23 [95%CI: 0.08-0.64])、糖尿病(sHR 5.62 [95%CI: 2.02-15.68])、白蛋白(sHR 0.34 [95%CI: 0.13-0.89])和血小板(sHR 0.99 [95%CI: 0.98-1.00])与失代偿相关。
  • 贝特类治疗患者中,药物应答(sHR 0.36 [95%CI: 0.14-0.95])、白蛋白(sHR 0.36 [95%CI: 0.16-0.81])和临床显著门脉高压(sHR 3.70 [95%CI: 1.17-11.70])与失代偿肝硬化相关。

关键数值与推荐

  • 奥贝胆酸应答与胆红素OR 0.21(95%CI: 0.06-0.73)和AST OR 0.97(95%CI: 0.95-0.99)相关。
  • 贝特类应答与AST OR 0.96(95%CI: 0.95-0.98)相关。
  • 奥贝胆酸治疗患者中,药物应答sHR 0.23(95%CI: 0.08-0.64),糖尿病sHR 5.62(95%CI: 2.02-15.68),白蛋白sHR 0.34(95%CI: 0.13-0.89),血小板sHR 0.99(95%CI: 0.98-1.00)。
  • 贝特类治疗患者中,药物应答sHR 0.36(95%CI: 0.14-0.95),白蛋白sHR 0.36(95%CI: 0.16-0.81),临床显著门脉高压sHR 3.70(95%CI: 1.17-11.70)。

临床怎么用

  • 决定奥贝胆酸和贝特类药物管理时应考虑生化和临床变量。
  • 对奥贝胆酸和贝特类药物的阳性应答可降低失代偿风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The landscape in primary biliary cholangitis (PBC) has changed with the advent of second-line treatments. However, the use of obeticholic acid (OCA) and fibrates in PBC-related cirrhosis is challenging. We assessed the impact of receiving a second-line therapy as a risk factor for decompensated cirrhosis in a real-world population with cirrhosis and PBC, and identify the predictive factors for decompensated cirrhosis in these patients. APPROACH AND RESULTS: Multicenter study enrolling 388 patients with PBC-cirrhosis from the Spanish ColHai registry. Biopsy (20%), ultrasound (59%), or transient elastography (21%) defined cirrhosis, and the presence of varices and splenomegaly defined clinically significant portal hypertension (CSPH). Paris-II and PBC OCA international study of efficacy criteria determined the response to ursodeoxycholic acid (UDCA), fibrates (n=93), and OCA (n=104). The incidence of decompensated cirrhosis decreased for UDCA versus OCA or fibrates in the real-world population, but they were similar considering the propensity score-matched cohort (UDCA 3.77 vs. second-line therapy 4.5 100 persons-year, respectively), as patients on second-line therapy exhibited advanced liver disease. Consequently, GGT, albumin, platelets, clinically significant portal hypertension, and UDCA response were associated with a decompensating event. OCA response (achieved in 52% of patients) was associated with bilirubin (OR 0.21 [95% CI: 0.06-0.73]) and AST (OR 0.97 [95% CI: 0.95-0.99]), while fibrate response (achieved in 55% of patients) with AST [OR 0.96 (95% CI: 0.95-0.98]). In patients treated with OCA, drug response (sHR 0.23 [95% CI: 0.08-0.64]), diabetes (sHR 5.62 [95% CI: 2.02-15.68]), albumin (sHR 0.34 [95% CI: 0.13-0.89]), and platelets (sHR 0.99 [95% CI: 0.98-1.00]) were related to decompensation. In patients treated with fibrate, drug response (sHR 0.36 (95% CI: 0.14-0.95]), albumin (sHR 0.36 (95% CI: 0.16-0.81]), and clinically significant portal hypertension (sHR 3.70 (95% CI: 1.17-11.70]) were associated with decompensated cirrhosis. CONCLUSIONS: Advanced PBC, rather than OCA and fibrates, was found to be associated with decompensating events. Therefore, biochemical and clinical variables should be considered when making decisions about the management of these drugs. Moreover, a positive response to OCA and fibrates reduced the risk of decompensation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ampuero J, Lucena A, Berenguer M, et al. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy. Hepatology. 2024. PMID: 38447019. doi:10.1097/HEP.0000000000000826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。